Does Medicare Cover Zepbound? 2026 Rules and the $50 Bridge

"Does Medicare cover Zepbound" has two correct answers in 2026, and which one applies to you depends entirely on why the drug is prescribed. Medicare has never been allowed to pay for drugs used purely for weight loss — but Zepbound carries a second FDA indication that slips through that exclusion, and starting this July, a federal demonstration program bypasses the exclusion altogether.

Direct answer: Yes — through two different doors. Door 1 (open now): Medicare Part D plans can cover Zepbound when it's prescribed for moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity, an FDA indication Zepbound has held since December 2024. Coverage depends on your plan's formulary and almost always requires prior authorization with a sleep study. Door 2 (opens July 1, 2026): the Medicare GLP-1 Bridge covers the Zepbound KwikPen for weight loss at a flat $50/month through December 31, 2027, for beneficiaries who meet BMI-based criteria. What Medicare still won't do in 2026 is cover Zepbound for weight loss through your regular Part D benefit — and the single-dose vials and pens aren't in the Bridge at all.

Lilly itself now advertises both doors: zepbound.lilly.com states that "millions with Medicare will be able to get Zepbound KwikPen for only $50/month starting July 1," subject to Medicare GLP-1 Bridge eligibility criteria.

Zepbound Medicare Coverage: Every Path in One Table

Zepbound Medicare Coverage for Sleep Apnea: The Part D Path

In December 2024, the FDA approved Zepbound to treat moderate-to-severe OSA in adults with obesity. That matters because Medicare's weight-loss exclusion only blocks drugs when used for weight loss — a GLP-1 prescribed for a different medically accepted indication is fair game for Part D. CMS confirmed this, listing OSA alongside type 2 diabetes and MASH as Part D-coverable GLP-1 indications.

The catch is execution:

• Formularies vary. Plans can cover Zepbound for OSA; not all do. Check your plan's formulary in Medicare's plan finder before assuming anything.
• Prior authorization is nearly universal. Expect to submit a sleep study (lab or home-based) confirming moderate-to-severe OSA, BMI documentation, and a statement that the prescription is for OSA — not weight.
• If it's not on formulary, you can request an exception. CMS explicitly requires Part D sponsors to run their normal formulary-exception process for OSA prescriptions rather than shunting people to the Bridge.
• Costs count toward the cap. Unlike the Bridge, Part D spending on Zepbound counts toward 2026's $2,100 out-of-pocket maximum, after which you pay $0 for the rest of the year.

Important: if you qualify for the OSA pathway, you cannot use the Bridge — CMS rules send anyone with a Part D-coverable indication through their Part D plan, even if their BMI also meets Bridge criteria.

Zepbound Medicare Coverage for Weight Loss: The $50 Bridge (From July 1, 2026)

The Medicare GLP-1 Bridge program is a CMS demonstration running July 1, 2026 through December 31, 2027 that covers weight-loss GLP-1s outside the normal Part D benefit. For Zepbound specifically:

• Only the KwikPen formulation is included. Single-dose vials and single-dose pens are excluded — if you've been buying $299-$449 LillyDirect vials, the $50 price requires switching to the multi-dose KwikPen.
• The copay is a flat $50 per monthly supply, every month, with manufacturers supplying the drug at a negotiated $245 net price.
• Eligibility is BMI-tiered, measured when you started therapy: BMI ≥35 alone; BMI ≥30 plus heart failure with preserved ejection fraction, uncontrolled hypertension, or CKD stage 3a+; or BMI ≥27 plus pre-diabetes, prior heart attack, prior stroke, or symptomatic peripheral artery disease.
• Plan type matters: you need a standalone PDP or an HMO/HMO-POS/local-or-regional-PPO Medicare Advantage drug plan.
• No sign-up. Your prescriber files a prior authorization with CMS's central processor on or after July 1, 2026, attesting you meet the criteria and are doing lifestyle modification alongside the drug.
• The $50 doesn't count toward your deductible, TrOOP, or the $2,100 cap, and Extra Help/LIS subsidies don't reduce it.

Wegovy (all forms) and Foundayo, Lilly's new GLP-1 pill, are the other two Bridge drugs — the full program rules, timeline, and exclusions are in our dedicated Bridge guide.

What Zepbound Costs on Medicare in 2026

That last row trips people up constantly: Lilly's $25 savings card legally excludes anyone on Medicare, Medicaid, or TRICARE. A Medicare beneficiary's discount options are the Bridge, the OSA pathway, or paying cash entirely outside insurance — covered in detail in our Zepbound coupon guide.

Which Zepbound Coverage Path Fits Your Situation

• You have diagnosed moderate-to-severe OSA and obesity: pursue Part D now. Ask your doctor to file prior authorization with your sleep study attached; request a formulary exception if Zepbound isn't listed.
• You want Zepbound for weight loss and meet a BMI tier: wait for July 1, 2026, then have your prescriber submit the Bridge prior authorization. Budget $50/month.
• You suspect sleep apnea but were never tested: a sleep study could open the Part D door today — and OSA is badly underdiagnosed in the Bridge's exact demographic.
• You have type 2 diabetes: you're in the wrong aisle — Part D covers Mounjaro, the diabetes-labeled tirzepatide, instead.
• None of the above: cash routes below.

If Your Part D Plan Denies Zepbound

Denials for OSA prescriptions are appealable. The sequence: ask the plan for a coverage determination with your prescriber's supporting statement → if denied, file a redetermination (first appeal) within 65 days → escalate to an independent review entity. Most successful Zepbound appeals hinge on documenting the OSA diagnosis clearly and showing the prescription is for the FDA-approved OSA indication, not weight loss. Our GLP-1 insurance coverage guide walks through appeal templates, and cheapest GLP-1 ranks the fallback options by price.

If You Can't Get Zepbound Covered at All

On Medicare but locked out until July — or not eligible at all? Yücca telehealth — online evaluation, doctor-prescribed compounded Semaglutide+ or Tirzepatide+ filled by a licensed US pharmacy, from $146/month, no insurance involved. (Partner link: we may earn a commission, at no extra cost to you.)

Frequently Asked Questions

Does Medicare cover Zepbound for weight loss in 2026? Not through regular Part D — the weight-loss exclusion still applies. But from July 1, 2026 through December 31, 2027, the Medicare GLP-1 Bridge covers the Zepbound KwikPen for weight loss at a flat $50/month for beneficiaries who meet BMI-based criteria.

Does Medicare cover Zepbound for sleep apnea? Yes, it can. Zepbound has been FDA-approved for moderate-to-severe OSA in adults with obesity since December 2024, which makes it Part D-coverable. Coverage depends on your plan's formulary and requires prior authorization with a sleep study.

How much is Zepbound with Medicare? On the OSA pathway, plan cost-sharing applies — roughly $160-190/month on average until you reach the $2,100 annual out-of-pocket cap. On the Bridge (from July 2026), it's a flat $50/month for the KwikPen.

Can Medicare patients use the Zepbound savings card? No. Lilly's $25 savings card excludes all government beneficiaries, including Medicare. Medicare patients can still pay cash through LillyDirect ($299-$449/month) since that bypasses insurance entirely.

Are Zepbound vials covered by the Medicare Bridge program? No. Only the KwikPen formulation is included in the Bridge. Single-dose vials and single-dose pens are explicitly excluded.

Which is better for me — the OSA pathway or the Bridge? You don't get to choose: CMS rules say anyone with a Part D-coverable indication (like OSA) must use Part D. The Bridge is only for people whose sole indication is weight management.

Last reviewed: June 13, 2026

Sources

• Medicare GLP-1 Bridge: Information for Medicare Beneficiaries — CMS
• Coming Soon: CMS to Provide $50 Monthly Access to GLP-1 Medications for Medicare Beneficiaries — CMS Newsroom
• Zepbound Coverage and Savings — zepbound.lilly.com
• Does Medicare Cover Zepbound for Sleep Apnea? — SleepApnea.org
• What to Know About the BALANCE Model for GLP-1s in Medicare and Medicaid and the Medicare GLP-1 Bridge — KFF
• White House Strikes GLP-1 Pricing Deal With Lilly, Novo — BioSpace
• What Medicare's Temporary Program Covering GLP-1s for Obesity Means for Beneficiaries — KFF